AML is a hematologic cancer that is clinically heterogeneous, with a wide range of clinical outcomes. DNA methylation changes are a hallmark of AML but are not routinely used as a criterion for risk ...

Duration of First Off-Treatment Interval Is Prognostic for Time to Castration Resistance and Death in Men With Biochemical Relapse of Prostate Cancer Treated on a Prospective Trial of Intermittent ...

Panelists advocate for a streamlined approach to diagnosing KMT2A-rearranged acute myeloid leukemia (AML) that includes standardized testing protocols (cytogenetics, fluorescence in situ hybridization ...

Patients 1 and 2 had bone marrow cytogenetic analyses and reverse transcriptase-polymerase chain reaction (RT-PCR) screening for chromosomal translocations performed at initial presentation. Patient 3 ...

This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and ...

Bionano announced a significant study published in the American Journal of Hematology demonstrating the utility of optical genome mapping (OGM) in detecting structural variants associated with ...

High-dose daunorubicin improved complete response rates in patients aged 60 and younger and survival in those younger than 50. Despite considerable advances during the past 20 years in the diagnostic ...

—According to researchers in Germany, the presence of additional cytogenetic or molecular markers included in current risk stratification systems, rather than the presence or absence of a trisomy 8, ...